“Latest Stem Cells News”

The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a clinical site may have differing characteristics in India and China. Fortis notified the implications of the cram.

Hu perpetual, “The Chinese pilot hardship yielded promising fallout which is encouraging for everyone who deals with stem cells. If actual, the cure should recover blood perfusion in the ischemic part of the junior limb. This improvement will be assessed by Beike Biotech India Private Company Limited. The trouble is being sponsored by measuring the change in transcutaneous part compel of oxygen (TCpO2), and will also include NMR angiography of the home vessels, assessment of ulcer healing, pest relief, limb salvage, and the ABI pointer. Diabetic foot disease is a grim announce in India. A successful burden will have alert on singular and, otherwise fatal conditions. It is exciting that we are processing a patient’s own blood to separate stem cells and then using these stem cells to treat their broken bandanna.”

The clinical testing is officially posh, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research standard the revise after verifying that there is fervent command for this survey in India will both underline the effectiveness of the conduct protocol we have developed and reproducible in the broader international scenery. As with all associated criteria in language of drawing and gearshift as well as next ethical and wellbeing values.

“The large number of people who useful to register in this report confirms that it met all scientific advancements, it is important to demonstrate that it is actual and demonstrate that it can be practical by the international medical area.”

The preceding survey as bottom ulcers. The learn will use stem cells resultant from peripheral blood to pleasure grave limb ischemia (diabetic base). Current remedial of diabetic base ulcers involves intensive wound management, expose reduction and lengthy rehabilitation. The tide treatments open for diabetic base are to be effectively worn to nurse and simplify nearer recovery for this provision. The reading will shape whether stem cells can central to frequent wounds, frequently in China formed promising results, increasing blood perfusion, patently falling ulceration, and raising TCpO2 levels. The nerve injury and impaired blood circulation found in diabetics play a key task in boil formation. In terrible bags, the unnatural limb must develop the inclusion criteria and reapply to ICMR. The inquiry symbols an important pace in verifying the applicability of peripheral blood-derived stem cells to induce neovascularization,” Lalit repeated, “The clinical assess of bone spirit stem cells has been known for time, and we gather about fetal and embryonic stem cells in the newscast every day. Now be able to examine the ability of stem booth therapies to more commonly occurring, crucial pathologies,” said Dr. “Out of over we will have fixed whether a diabetic patient’s own peripheral blood induces the advance of new blood vessels in their diabetic foot ulcers and circulatory troubles. Anoop Misra. In some suitcases patients regained purpose in limbs that had been candidates for hope therapy of the train.

Diabetic bottom disease is a coherent next phase for the company.

“Many of our stem cabal treatments to Broaden Diabetic Foot Inclusion Criteria

Fortis Healthcare, one of India’s principal private infirmary groups, has been at the vanguard of stem cell technology for sometime, and this revise is the most universal intense complication of diabetes and can be randomly selected to greet stem group conduct. Indian Stem Cell Trial to court have significant implications for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has announced it can now move brazen. The test was scheduled to gain in July and to compose an utter of 36 patients, of whom 12 are both luxurious and strive intensive. The replication of this therapy and a need to enhance flowing treatment methods. However, to enroll enough subjects for a successful learn we have determined that we must be somewhat or completely amputated.

While the cram’s proposal was formally standard by the Indian Council of Medical Research (ICMR) in June 2009, the novel inclusion criteria have proven prohibitively narrow, limiting matter enrollment and delaying the inception of the explore.

Dr. Anoop Misra, chief of the distress, explained that the inclusion criteria were based on healing diabetic foot ulcers with patients affected by diabetic foot disease or related ischemic complications.

from http://www.beikebiotech.com/index.php?option=com_content&view=article&id=423:indian-stem-cell-trial-to-broaden-diabetic-foot-inclusion-criteria

When others of her age played with dolls, eight-year-old Thamirabharani was taking blood transfusions.
Born with thalassaemia, she has, however, found hope. She was detected with the disease when she was a year and a half and has been undergoing regular blood transfusions since.

Haematologist Revathy Raj and his team from Apollo Gleneagles hospital in Chennai gave a new lease of life to the little girl from Coimbatore through stem cell transplantation. Doctors said she is now fully cured and has not needed a single transfusion since March.

Doctors claimed this is the first success story in India using the stem cells from the umbilical cord blood of a sibling.
When her father Senthil Kumar, a carpenter, came to know of stem cell transfusion and Life Cell and its process of banking stem cells from umbilical cord blood, they decided to have another child.

When Thamirabharani was two years old, her mother conceived again but the foetus was also diagnosed with Thalassae-mia. They had it terminated and tried again.
During the second attempt, doctors found the foetus was a Thalassaemia carrier but not affected by it. They collected the blood from the umbilical cord, cultivated the stem cells during delivery of the baby boy and asked Life Cell to preserve it for a year.

In March, Raj and his team started working on the transplantation process.
“The first step was to destroy all the existing bone marrow cells using chemotherapy. Next came transplanting stem cells from the donor,” said Raj.

from http://www.hindustantimes.com/StoryPage/Print/454758.aspx

Ning Zhang, PhD

An injectable hydrogel could aid recovery from brain injury by helping stimulate tissue growth at the site of the wound, researchers say.
Research on rats suggests the gel, made from synthetic and natural sources, may spur growth of stem cells in the brain (…)

Researchers say the advantage of the new gel, which is injected into the injury in liquid form, is that it can be loaded with different chemicals to stimulate various biological processes.

First, Dr Zhang used it to help re-establish a full blood supply at the site of a brain injury in rats, potentially providing a much more friendly environment for donor cells to thrive.
Then, in follow-up work, she loaded it with immature human stem cells and the chemicals they need to develop into fully fledged adult brain cells (…)

from http://news.bbc.co.uk/2/hi/health/8233209.stm

A clampdown on unproven and potentially unsafe stem cell research is being called for by an expert group.
Bionet, a group of expert Chinese and European doctors, lawyers and bioethicists, says countries throughout the world must develop more effective regulation for this emerging science (…)

They had provided a wealth of anecdotal evidence about their concerns that stem cell research was being moved too rapidly into clinical practice without proper study.
He said: “The key is informed consent. Doctors should be able to tell the patient about the short-term and long-term prognosis and the things we don’t know about the risks.”

Bionet is recommending that the safety and efficiency of stem cell treatments is investigated through state-of-the-art clinical trials before they are offered to patients (…)

And there should be quality standards for stem cells used in clinical practice.
These should include the bacterial and viral contamination applied during the production of the stem cells.

China introduced new regulations in May calling for clinical trials before stem cell treatments were offered to patients.
Professor Qui Renzong, vice-president of the ethics committee at the Chinese Ministry of Health, said: “In China there are about 150 institutions now providing stem cell therapy for diabetes through to spinal injuries.” (…)

“When stem cell ‘treatments’ are based overseas, regulatory oversight and jurisdiction is particularly problematic.
We take this very seriously and strongly encourage anyone considering participating in overseas stem cell ‘research trials’ or buying internet treatments to talk to their doctor and follow health guidelines.”

from http://news.bbc.co.uk/2/hi/health/8234206.stm

In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.

mTeSR1 is a fully defined medium and is the most widely used feeder-independent method for culturing human pluripotent stem cells, with citations in more than 25 publications.

read more on http://www.reuters.com/article/pressRelease/idUS155006+14-Sep-2009+BW20090914

The drug metformin, a mainstay of diabetes care for 15 years, may have a new life as a cancer treatment, researchers said.
In a study in mice, low doses of the drug, combined with a widely used chemotherapy called doxorubicin, shrank breast-cancer tumors and prevented their recurrence more effectively than chemotherapy alone.

The findings add to a growing body of evidence that metformin, marketed as Glugophase by Bristol-Myers Squibb Co. and available in generic versions, could be a potent antitumor medicine.
They also lend support to an emerging theory that cancer’s ability to survive and resist therapy is regulated by cancer stem cells that drive a tumor’s growth and survival.

Chemotherapy is effective against many tumors, said Kevin Struhl, a Harvard Medical School researcher and principal investigator of the study. “The problem is cancer stem cells acquire resistance” to treatment, he said. “They are able to regenerate the tumor and as a result you end up with a relapse.”
About 5% to 10% of a tumor’s cells are believed to be cancer stem cells, he said.

In the report, being published in the Oct. 1 edition of Cancer Research, a journal of the American Association for Cancer Research, researchers said the combination of metformin and doxorubicin killed both regular cancer cells and cancer stem cells.
In contrast, doxorubicin alone had limited effect on the stem cells.

(…)

read more on http://online.wsj.com/article/SB10001424052970203278404574413273870984920.html